Mar 18, 2025 4:01 pm EDT Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
Mar 17, 2025 8:00 am EDT Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Expo
Mar 11, 2025 10:20 pm EDT Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
Mar 10, 2025 7:00 am EDT Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
Mar 07, 2025 4:01 pm EST Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Feb 12, 2025 7:00 am EST Mineralys Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Feb 05, 2025 4:05 pm EST Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Feb 04, 2025 8:00 am EST Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria
Jan 08, 2025 8:00 am EST Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
